著者
横山 信治
出版者
日本膜学会
雑誌
(ISSN:03851036)
巻号頁・発行日
vol.32, no.1, pp.2-10, 2007 (Released:2015-06-18)
被引用文献数
1 1

HDL is a strong negative risk factor for atherosclerotic disease, and perhaps more potent target to prevent and cure the disease than LDL in Japan. However, no specific compound to raise HDL is clinically available, so that there is no firm evidence for the clinical effect of the increase of HDL. As our knowledge of regulation of HDL metabolism has advanced significantly in the past several years, a great effort is being made to develop such compounds, by inhibiting catabolic reaction of HDL, and stimulating maturation and biogenesis of HDL.

言及状況

外部データベース (DOI)

Twitter (1 users, 1 posts, 0 favorites)

https://t.co/Icd629UudJ

収集済み URL リスト